International collaboration on high-priority TTP questions.
IWG TTP supports investigator-led international collaboration, shared scientific questions, project teams, publications, and consensus work across TTP and related TMAs.
Current scientific priorities
Areas of active discussion and development.
Updated TTP terminology and definitions
Continuing international discussion about clinically meaningful terminology and outcome definitions as monitoring and therapies evolve.
Congenital TTP event definitions and long-term manifestations
Refining how acute, subacute, and chronic manifestations are described and studied, including questions relevant to prophylaxis and long-term outcomes.
Recombinant ADAMTS13 surveillance
Discussing emerging scientific issues related to recombinant ADAMTS13, including surveillance and antibody-assay considerations.
Evolving iTTP treatment strategies
Exploring how treatment pathways may change with caplacizumab, immunosuppression, plasma exchange strategies, and future roles for ADAMTS13 replacement.
Important: These are areas of scientific discussion and work in development. They should not be interpreted as final IWG TTP clinical guidance unless formally approved and published.
Scientific Publications
Publications of the IWG TTP
Explore consensus reports and collaborative original research developed through the International Working Group on TTP, including the Capla 1000+ international research project.
How projects move forward
Member-proposed. Board-reviewed. Investigator-led.
Participating members may propose projects to the Board. Priority is given to collaborative, high-impact, feasible work. Once approved, projects are led by investigators designated through the project process, with voluntary participation and project-specific teams formed as needed.
Data remain under the control of lead or contributing investigators unless otherwise agreed. Publications and outputs are expected to reflect contribution, scientific rigor, transparency, ethical standards, and—where possible—open access.